Avalo Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q3 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Avalo Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2016 to Q3 2024.
  • Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$14K, a 275% decline year-over-year.
  • Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$9K, a 128% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $14K, a 50% decline from 2022.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $28K.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$196K, a 93% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$9K -$14K -$22K -275% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $13K $7K $0 0% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $13K $7K -$1K -12.5% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-07-11
Q4 2023 $14K -$9K -$18K -200% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $32K $8K +$3K +60% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $29K $7K +$2K +40% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $27K $8K -$1K -11.1% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-07-11
Q4 2022 $28K $9K +$25K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $3K $5K -$3K -37.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $6K $5K +$204K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$198K $9K -$2K -18.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$196K -$16K +$169K +91.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$365K $8K +$5K +167% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$370K -$199K +$255K +56.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$625K $11K +$2.17M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$2.79M -$185K -$160K -627% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$2.63M $3K -$119K -97.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$2.51M -$454K -$507K -949% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-02
Q1 2020 -$2.01M -$2.16M -$2.29M -1751% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $280K -$25.4K +$116K +82% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 $164K $122K +$69.2K +132% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $95K $53.4K +$37.1K +227% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $57.9K $131K +$107K +461% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$49.5K -$142K +$1.12M +88.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$1.17M $52.4K -$3.18M -98.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $2.01M $16.4K +$16.4K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $1.99M $23.3K +$23.3K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $1.97M -$1.26M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $3.23M +$3.23M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $0 Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $0 Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q3 2016 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.